Sr One Capital Management, L.P. 13F annual report
Sr One Capital Management, L.P. is an investment fund managing more than $319 billion ran by Sasha Keough. There are currently 9 companies in Mr. Keough’s portfolio. The largest investments include Arcellx, Inc. and CRISPR Therapeutics AG, together worth $186 billion.
$319 billion Assets Under Management (AUM)
As of 6th August 2024, Sr One Capital Management, L.P.’s top holding is 2,346,630 shares of Arcellx, Inc. currently worth over $130 billion and making up 40.5% of the portfolio value.
In addition, the fund holds 1,048,951 shares of CRISPR Therapeutics AG worth $56.7 billion, whose value fell 35.5% in the past six months.
The third-largest holding is Ars Pharmaceuticals, Inc. worth $34.1 billion and the next is Alumis Inc. worth $26.1 billion, with 1,959,896 shares owned.
Currently, Sr One Capital Management, L.P.'s portfolio is worth at least $319 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Sr One Capital Management, L.P.
The Sr One Capital Management, L.P. office and employees reside in Wayne, Pennsylvania. According to the last 13-F report filed with the SEC, Sasha Keough serves as the General Counsel and CCO at Sr One Capital Management, L.P..
Recent trades
In the most recent 13F filing, Sr One Capital Management, L.P. revealed that it had opened a new position in
CRISPR Therapeutics AG and bought 1,048,951 shares worth $56.7 billion.
This means they effectively own approximately 0.1% of the company.
CRISPR Therapeutics AG makes up
71.3%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Mineralys Therapeutics Inc. by buying
222,222 additional shares.
This makes their stake in Mineralys Therapeutics Inc. total 2,016,822 shares worth $23.6 billion.
On the other hand, there are companies that Sr One Capital Management, L.P. is getting rid of from its portfolio.
Sr One Capital Management, L.P. closed its position in Effector Therapeutics Inc on 13th August 2024.
It sold the previously owned 6,822,114 shares for $4.03 billion.
Sasha Keough also disclosed a decreased stake in Arcellx, Inc. by 0.4%.
This leaves the value of the investment at $130 billion and 2,346,630 shares.
One of the smaller hedge funds
The two most similar investment funds to Sr One Capital Management, L.P. are Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet Ltd and Etf Portfolio Partners. They manage $319 billion and $319 billion respectively.
Sasha Keough investment strategy
Sr One Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 24.9% of
the total portfolio value.
The fund focuses on investments in the Switzerland as
11.1% of the portfolio companies
are based in the Switzerland.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.52 billion.
The complete list of Sr One Capital Management, L.P. trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Arcellx, Inc. |
40.54%
2,346,630
|
$129,510,510,000 | 40.55% |
| CRISPR Therapeutics AG |
Opened
1,048,951
|
$56,653,844,000 | 17.74% |
| Ars Pharmaceuticals, Inc. |
No change
4,012,903
|
$34,149,805,000 | 10.69% |
| Alumis Inc. |
Opened
1,959,896
|
$26,066,617,000 | 8.16% |
| Mineralys Therapeutics Inc. |
12.38%
2,016,822
|
$23,596,817,000 | 7.39% |
| Design Therapeutics, Inc. |
No change
6,526,476
|
$21,863,695,000 | 6.85% |
| Nkarta, Inc. |
150.00%
3,333,333
|
$19,699,998,000 | 6.17% |
| Engene Holdings Inc. |
Opened
500,000
|
$4,715,000,000 | 1.48% |
| Effector Therapeutics Inc |
Closed
6,822,114
|
$4,025,047,000 | |
| Kala Bio Inc. |
Opened
443,661
|
$3,145,556,000 | 0.98% |
| No transactions found | |||
| Showing first 500 out of 10 holdings | |||
Hedge funds similar to Sr One Capital Management, L.P.
- Whitcomb & Hess
- High Note Wealth
- Geometric Wealth Advisors
- Boltwood Capital Management
- Kidder Stephen W
- Citizens & Northern Corp
- Etf Portfolio Partners
- Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet Ltd
- Berkeley Capital Partners
- Xcel Wealth Management
- Karpas Strategies
- Court Place Advisors
- Contrarian Capital Management, L.L.C
- Kerrisdale Advisers